ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
The new OS results came from the Phase III INAVO120 study evaluating an Itovebi triple combination therapy.
Therapy Area
Bayer’s Eylea set for longer treatment intervals to challenge Roche’s Vabysmo
FDA approves GSK’s Nucala to treat COPD
Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push
Wegovy and Zepbound costs capped at $200 in new Evernorth programme
Lilly’s Kisunla marketing for Alzheimer’s authorised in Australia
Moderna shares down after pulling Covid-flu combo vaccine application
Viz.ai, Sanofi and Regeneron to link for COPD management
